Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04760769
Registration number
NCT04760769
Ethics application status
Date submitted
12/02/2021
Date registered
18/02/2021
Titles & IDs
Public title
Open-label Trial in Parkinson's Disease (PD)
Query!
Scientific title
58-Week Open-label Trial of Tavapadon in Parkinson's Disease (TEMPO-4 Trial)
Query!
Secondary ID [1]
0
0
2019-002952-17
Query!
Secondary ID [2]
0
0
CVL-751-PD-004
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
TEMPO-4
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Parkinson Disease
0
0
Query!
Condition category
Condition code
Neurological
0
0
0
0
Query!
Parkinson's disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Tavapadon
Experimental: Tavapadon - Participants will receive a Tavapadon tablet at a dose of 5 milligrams (mg) to 15 mg once daily (QD) orally during 58-week treatment period.
Treatment: Drugs: Tavapadon
Participants will receive Tavapadon at a dose of (5 to 15) mg QD, orally during a 58-week treatment period.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Query!
Assessment method [1]
0
0
An AE is any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of trial intervention, whether or not considered related to the trial intervention. Any AE occurring following the start of treatment or occurring before treatment but increasing in severity afterward were counted as treatment-emergent AE (TEAE). Clinically significant abnormalities in Clinical Laboratory Evaluations, Vital Signs, Physical and Neurological evaluations and ECGs will be reported as TEAEs.
Query!
Timepoint [1]
0
0
62 Weeks
Query!
Primary outcome [2]
0
0
Number of Participants Who Discontinued Study Treatment
Query!
Assessment method [2]
0
0
A participant may discontinue the study treatment due to any of the following reasons: adverse event, death, worsening of PD symptoms to such an extent that, in the judgement of the investigator, the participant requires additional anti-PD medications, treatment with a prohibited concomitant medication, noncompliance with the trial schedule or procedures, withdrawal of consent, pregnancy, investigator discretion.
Query!
Timepoint [2]
0
0
62 Weeks
Query!
Primary outcome [3]
0
0
Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease Rating Scale (QUIP-RS)
Query!
Assessment method [3]
0
0
QUIP-RS is a global screening instrument that assesses impulse control disorders (ICDs) and related disorders (punding, hobbyism, and dopamine dysregulation syndrome) in participants with PD. The QUIP-RS has 4 primary questions that pertain to commonly reported thoughts, urges/desires, and behaviors associated with ICDs, each of which is applied to 4 ICDs (compulsive gambling, buying, eating, sexual behavior) and 3 related disorders (medication use, punding, and hobbyism). The QUIP-RS uses a 5-point Likert scale (score 0-4 \[0 means "never" and 4 means "very often"\] for each question) to gauge the frequency of behaviors. Scores for each ICD and related disorder range from 0 to 16, with a higher score indicating greater severity (frequency) of symptoms. The total QUIP-RS score for all ICDs and related disorders combined ranges from 0 to 112.
Query!
Timepoint [3]
0
0
58 Weeks
Query!
Primary outcome [4]
0
0
Epworth Sleepiness Scale (ESS)
Query!
Assessment method [4]
0
0
ESS is a scale that is intended to measure daytime sleepiness. It assesses the likelihood of dozing off or falling asleep in the following common situations: sitting and reading, sitting inactive in a public place as a passenger in a car for an hour or more without stopping for a break, lying down to rest when circumstances permit, sitting and talking to someone, sitting quietly after a meal without alcohol, and in a car while stopped for a few minutes in traffic or at a light. Each situation is rated as 0 = would never nod off, 1 = slight chance of nodding off, 2 = moderate chance of nodding off, or 3 = high chance of nodding off. A score greater than or equal to (\> =) 10 indicates that the participant may need to get more sleep, improve sleep practices, or seek medical attention to determine why he or she is sleepy.
Query!
Timepoint [4]
0
0
58 Weeks
Query!
Primary outcome [5]
0
0
Columbia-Suicide Severity Rating Scale (C-SSRS)
Query!
Assessment method [5]
0
0
C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent).
Query!
Timepoint [5]
0
0
60 Weeks
Query!
Primary outcome [6]
0
0
Study Medication Withdrawal Questionnaire (SMWQ)
Query!
Assessment method [6]
0
0
SMWQ is a questionnaire to assess withdrawal symptoms subsequent to completion of dosing with Investigational medicinal product (IMP). The SMWQ is a modification of the Amphetamine Withdrawal Questionnaire, in which the first question "Have you been craving amphetamine or methamphetamine?" is replaced with "Have you been craving the trial medication?" This change is intended to prevent bias by implying that the trial medication might be an amphetamine or amphetamine-like stimulant when presented with the survey. Participants will complete the SMWQ onsite when they are at a designated trial visit; on days when the participant is not onsite, they will complete the SMWQ remotely.
Query!
Timepoint [6]
0
0
60 Weeks
Query!
Primary outcome [7]
0
0
Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II and III
Query!
Assessment method [7]
0
0
The MDS-UPDRS is a multidimensional scale that assesses the motor and non-motor impacts of PD across 4 parts. Part I, non-motor aspects of experiences of daily living, comprises 13 items, 6 of which are rated by the physician (Part IA) and 7 of which are rated by the participant (Part IB). Part II, motor aspects of experiences of daily living, comprises 13 items that are rated by the participant. Part III, motor examination, comprises 18 items that are assessed by the investigator (resulting in 33 scores by location and lateralization). Part IV, motor complications, comprises 6 item (3 items for dyskinesia and 3 items for fluctuation) and requires the physician to use historical and objective information to assess dyskinesia and motor fluctuations. Each item of all the parts will be rated on a scale from 0 to 4 on which 0 = normal, 1=slight, 2=mild, 3=moderate, and 4=severe. Change from baseline in MDS-UPDRS parts I, II and III combined score will be assessed.
Query!
Timepoint [7]
0
0
60 Weeks
Query!
Primary outcome [8]
0
0
Change From Baseline in the Hauser diary
Query!
Assessment method [8]
0
0
The Hauser diary (Hauser et al, 2000) assesses participant-defined clinical status over a period of time and provides a tool for assessment of the change in "off" time and "on" time with troublesome dyskinesia (which is a more accurate reflection of clinical response than "off" time alone). The Hauser diary asks participants to rate their mobility for each 30-minute period and to record their status for the majority of the period in 1 of 5 categories as: "on" time without dyskinesia, "on" time with nontroublesome dyskinesia, "on" time with troublesome dyskinesia, "off" time, or asleep.
Query!
Timepoint [8]
0
0
58 Weeks
Query!
Primary outcome [9]
0
0
Change From Baseline in the EuroQol 5 Dimension 5 Level (EQ-5D-5L) Index
Query!
Assessment method [9]
0
0
EQ-5D-5L is a survey instrument used for participant-reported outcome that measures health in 5 dimensions. The EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each has 5 levels of perceived problems (1 = no problem, 2 = slight problems, 3 = moderate problems, 4 = severe problems, 5 = extreme problems). Participant selects an answer for each of 5 dimensions considering the response that best matches his/her health "today". The digits for the 5 dimensions are combined into a 5-digit number that describes the participant's health state.
Query!
Timepoint [9]
0
0
Baseline (Day 1), Weeks 32 and 58
Query!
Primary outcome [10]
0
0
Change From Baseline in the EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scores (VAS)
Query!
Assessment method [10]
0
0
EQ-5D-5L VAS is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. The EQ-5D-5L VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine).
Query!
Timepoint [10]
0
0
Baseline (Day 1), Weeks 32 and 58
Query!
Eligibility
Key inclusion criteria
Key
Rollover participants are eligible for the study if they met the following inclusion criteria:
* Participants who complete the 27-week double-blind Treatment Period of Trial CVL-751-PD-001 (NCT04201093) or Trial CVL-751 PD-003 (NCT04542499) or the 27-week double-blind Treatment Period and 10-day Safety/Withdrawal Assessment Period of Trial CVL-751-PD-002 (NCT04223193) and enter this trial within 72 hours after completing the last trial visit in the double-blind trial. Rollover participants from Trial CVL-751-PD-003 must continue to use levodopa/carbidopa (or levodopa/benserazide) for the duration of the trial.
* Sexually active men or women of childbearing potential must agree to use acceptable (at minimum) or highly effective birth control, or remain abstinent during the trial and for 4 weeks after the last dose of trial treatment.
* Participants who are capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol.
* Participants who are willing and able to refrain from any PD medications that are not permitted by the protocol (including dopaminergic agents) throughout participation in the trial.
* Participant who, in the judgement of the investigator, demonstrated adequate compliance with the IMP and protocol requirements in the double-blind trial.
Key
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
Rollover participants are excluded from the trial if any of the following met:
* Participants who do not enroll in this open-label trial within 72 hours after completing the last trial visit in the double-blind trial
* Participants who answer "yes" on the C-SSRS Suicidal Ideation Item 4 or Item 5 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan, or Active Suicidal Ideation with Specific Plan and Intent) and whose most recent episode meeting the criteria for C-SSRS Item 4 or Item 5 occurred within the last 6 months, OR Participants who answer "yes" on any of the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior) and whose most recent episode meeting the criteria for any of these 5 C-SSRS Suicidal Behavior Items occurred within the last 2 years, OR Participants who, in the opinion of the investigator, present a serious risk of suicide.
* Participants who had previously been enrolled in this open-label trial and had subsequently withdrawn.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
NA
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
24/02/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/01/2026
Query!
Actual
Query!
Sample size
Target
1200
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Query!
Recruitment hospital [1]
0
0
Erina, New South Wales - Erina
Query!
Recruitment hospital [2]
0
0
Kogarah - Kogarah
Query!
Recruitment hospital [3]
0
0
Sydney, New South Wales - Sydney
Query!
Recruitment hospital [4]
0
0
Woolloongabba, Queensland - Woolloongabba
Query!
Recruitment hospital [5]
0
0
Clayton, Victoria - Clayton
Query!
Recruitment hospital [6]
0
0
Parkville, Victoria - Parkville
Query!
Recruitment postcode(s) [1]
0
0
2250 - Erina
Query!
Recruitment postcode(s) [2]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [3]
0
0
2050 - Sydney
Query!
Recruitment postcode(s) [4]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [5]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [6]
0
0
3050 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kansas
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maine
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Massachusetts
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Nevada
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New York
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
North Carolina
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Ohio
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Pennsylvania
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Tennessee
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Texas
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Vermont
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Virginia
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Washington
Query!
Country [22]
0
0
Bulgaria
Query!
State/province [22]
0
0
Pleven
Query!
Country [23]
0
0
Bulgaria
Query!
State/province [23]
0
0
Sofia
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Ontario
Query!
Country [25]
0
0
Czechia
Query!
State/province [25]
0
0
Chocen
Query!
Country [26]
0
0
Czechia
Query!
State/province [26]
0
0
Czech Republic
Query!
Country [27]
0
0
Czechia
Query!
State/province [27]
0
0
Prague
Query!
Country [28]
0
0
Czechia
Query!
State/province [28]
0
0
Rychnov Nad Knežnou
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Creteil
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Bron
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Grenoble
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Nancy
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Nîmes cedex 09
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Strasbourg
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Toulouse
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Muenster
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Bad Homburg
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Berlin
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Bochum
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Gera
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Haag In Oberbayern
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Muenchen
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Stadtroda
Query!
Country [44]
0
0
Hungary
Query!
State/province [44]
0
0
Budapest
Query!
Country [45]
0
0
Hungary
Query!
State/province [45]
0
0
Pécs
Query!
Country [46]
0
0
Hungary
Query!
State/province [46]
0
0
Tatabánya
Query!
Country [47]
0
0
Israel
Query!
State/province [47]
0
0
Haifa
Query!
Country [48]
0
0
Israel
Query!
State/province [48]
0
0
Petah Tiqva
Query!
Country [49]
0
0
Israel
Query!
State/province [49]
0
0
Ramat Gan
Query!
Country [50]
0
0
Israel
Query!
State/province [50]
0
0
Tel Aviv
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Cassino
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Milano
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Padova
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
Pisa
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Rome
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Torino
Query!
Country [57]
0
0
Poland
Query!
State/province [57]
0
0
Cracow
Query!
Country [58]
0
0
Poland
Query!
State/province [58]
0
0
Siemianowice Slaskie
Query!
Country [59]
0
0
Poland
Query!
State/province [59]
0
0
Bydgoszcz
Query!
Country [60]
0
0
Poland
Query!
State/province [60]
0
0
Katowice
Query!
Country [61]
0
0
Poland
Query!
State/province [61]
0
0
Krakow
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Kraków
Query!
Country [63]
0
0
Poland
Query!
State/province [63]
0
0
Lublin
Query!
Country [64]
0
0
Poland
Query!
State/province [64]
0
0
Warsaw
Query!
Country [65]
0
0
Serbia
Query!
State/province [65]
0
0
Belgrade
Query!
Country [66]
0
0
Spain
Query!
State/province [66]
0
0
Alicante
Query!
Country [67]
0
0
Spain
Query!
State/province [67]
0
0
Barcelona
Query!
Country [68]
0
0
Spain
Query!
State/province [68]
0
0
Madrid
Query!
Country [69]
0
0
Spain
Query!
State/province [69]
0
0
San Sebastian
Query!
Country [70]
0
0
Spain
Query!
State/province [70]
0
0
Terrassa
Query!
Country [71]
0
0
Spain
Query!
State/province [71]
0
0
Valencia
Query!
Country [72]
0
0
Ukraine
Query!
State/province [72]
0
0
Zaporiizhzhya
Query!
Country [73]
0
0
Ukraine
Query!
State/province [73]
0
0
Lviv
Query!
Country [74]
0
0
Ukraine
Query!
State/province [74]
0
0
Vinnitsa
Query!
Country [75]
0
0
Ukraine
Query!
State/province [75]
0
0
Zaporizhzhya
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Cerevel Therapeutics, LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the safety and efficacy of long-term administration of flexible doses of tavapadon in participants with Parkinson's Disease.
Query!
Trial website
https://clinicaltrials.gov/study/NCT04760769
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Cari Combs, MD
Query!
Address
0
0
Cerevel Therapeutics, LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT04760769